Comparison of neoadjuvant chemotherapy response and prognosis between HR-low/HER2-negative BC and TNBC: an exploratory real-world multicentre cohort study

Jing Peng, Yue Hong, Qitong Chen, Feng Xu, Danhua Zhang, Jia Yao, Qiongyan Zou, Liqin Yuan, Lun Li, Long Qian, Liqiu Liao, Mingwen Liu, Xuan Liu, Shouman Wang, Wenjun YiFrontiers in Endocrinology 2024 · DOI

TL;DR

This multicenter study reveals that breast cancers with low hormone receptor expression (HR-low/HER2-negative) respond to chemotherapy similarly to triple-negative breast cancer (TNBC). However, HR-low patients who fail to achieve a pathological complete response (pCR) face a significantly worse prognosis than their TNBC counterparts, highlighting a critical need for more intensive post-surgical treatment strategies for this "gray zone" subtype.

What Problem Does This Paper Address?

Breast cancer is traditionally categorized by the presence of Estrogen Receptors (ER), Progesterone Receptors (PR), and HER2. Patients with even 1% receptor expression are often classified as "HR-positive" and treated with endocrine therapy. However, a growing body of evidence suggests that "HR-low" tumors (1-10% expression) behave more like "HR-negative" or triple-negative breast cancers (TNBC) at a molecular level.

The challenge lies in the "gray zone": should HR-low patients be treated like standard HR-positive patients, or do they require the aggressive chemotherapy and intensive adjuvant (post-surgery) protocols typically reserved for TNBC? This paper investigates whether HR-low tumors respond to neoadjuvant chemotherapy (NAC)—treatment given before surgery to shrink tumors—in the same way TNBC does, and how their long-term survival outcomes compare in a real-world clinical setting.

Methods

The researchers conducted a retrospective multicenter cohort study involving 288 patients treated at three breast centers in Hunan Province, China, between 2015 and 2022.

To ensure a fair comparison between the HR-low group (70 patients) and the TNBC group (218 patients), the authors employed Inverse Probability of Treatment Weighting (IPTW). This statistical technique uses propensity scores to balance baseline characteristics (like age, tumor stage, and grade) between groups, effectively mimicking the balance of a randomized controlled trial in an observational dataset.

The primary metrics evaluated were:

  • Pathological Complete Response (pCR): The total disappearance of invasive cancer in the breast and lymph nodes after chemotherapy.
  • Event-Free Survival (EFS): The time from the start of treatment until disease progression, recurrence, or death.

Datasets

The study utilized a real-world clinical dataset of 288 patients:

  • HR-low/HER2-negative group: 70 cases (ER or PR expression between 1-10%).
  • TNBC group: 218 cases (ER and PR <1%).
  • Source: Department of Breast Surgery at Second Xiangya Hospital, Xiangya Hospital, and the First People’s Hospital of Xiangtan City.

Key Insights and Ideas

  • Biological Mimicry: The study confirms that HR-low tumors are "TNBC-like" in their initial response to chemotherapy. Both groups showed nearly identical rates of tumor shrinkage and total clearance (pCR).
  • The "Non-pCR" Survival Gap: The most striking finding was the divergence in survival for patients who did not achieve pCR. While TNBC patients without pCR had a 3-year EFS of 69.73%, the HR-low group dropped to 57.39%.
  • The Treatment Paradox: Why did HR-low patients fare worse? The authors suggest a "treatment gap." In modern clinical practice, TNBC patients who don't reach pCR often receive intensive "adjuvant" therapy (like capecitabine). HR-low patients, however, are often transitioned to standard endocrine therapy, which may be insufficient for these biologically aggressive, basal-like tumors.
  • Reclassifying Risk: The results argue that HR-low status should be viewed as a high-risk clinical marker, signaling that these patients may need the same intensive follow-up protocols as TNBC patients.

Key Results

  • Chemotherapy Response: There was no statistically significant difference in pCR rates between HR-low (27.1%) and TNBC (28.0%) (P = 1.000).
  • Clinical Benefit: The Objective Response Rate (ORR) was also similar: 76.9% for HR-low vs. 78.3% for TNBC.
  • Prognosis (Non-pCR): For patients who did not achieve pCR, the 3-year EFS was significantly lower in the HR-low group (57.39%) compared to the TNBC group (69.73%).
  • Prognosis (pCR): Patients in both groups who achieved pCR had excellent outcomes, with 3-year EFS rates of 94.74% (HR-low) and 89.70% (TNBC).

Limitations and Future Work

The authors acknowledge several limitations:

  1. Sample Size: The HR-low group was relatively small (70 patients), which may limit the statistical power to detect subtle differences.
  2. Retrospective Nature: As a real-world study, there is a risk of bias in how data was recorded across different centers.
  3. Follow-up Duration: A 3-year follow-up is relatively short for breast cancer; longer-term data is needed to confirm overall survival (OS) trends.
  4. Future Direction: The study highlights the urgent need for prospective randomized trials to determine if giving HR-low patients intensive TNBC-style adjuvant therapies (like capecitabine) can close the survival gap for those who don't achieve pCR.

Summary updated

Abstract

In the real world, the therapeutic effects of NAC for HR-low/HER2-negative BCs and TNBCs were similar. EFS of patients with non-pCR in the HR-low/HER2-negative BC group was inferior to that of the TNBC group with non-pCR, suggesting that it is necessary to explore new adjuvant intensive therapy strategies for these patients.
BibTeX
@inproceedings{peng2024comparison,
  author = {Jing Peng and Yue Hong and Qitong Chen and Feng Xu and Danhua Zhang and Jia Yao and Qiongyan Zou and Liqin Yuan and Lun Li and Long Qian and Liqiu Liao and Mingwen Liu and Xuan Liu and Shouman Wang and Wenjun Yi},
  title = {{Comparison of neoadjuvant chemotherapy response and prognosis between HR-low/HER2-negative BC and TNBC: an exploratory real-world multicentre cohort study}},
  booktitle = {Frontiers in Endocrinology},
  year = {2024},
  doi = {10.3389/fendo.2024.1347762},
}
Figure